Literature DB >> 22079529

Adjuvant radiotherapy after extrapleural pneumonectomy for mesothelioma. Prospective analysis of a multi-institutional series.

Sandro Tonoli1, Paola Vitali, Vieri Scotti, Filippo Bertoni, Luigi Spiazzi, Barbara Ghedi, Fabrizio Banci Buonamici, Livia Marrazzo, Gabriele Guidi, Icro Meattini, Paolo Bastiani, Maurizio Amichetti, Marco Schwarz, Stefano Maria Magrini.   

Abstract

BACKGROUND AND
PURPOSE: To evaluate survival, locoregional control and toxicity in a series of 56 mesothelioma patients treated from May 2005 to May 2010 with post-operative radiotherapy after extrapleural pneumonectomy (EPP) in three Italian Institutions (Brescia, Florence, and Modena).
MATERIAL AND METHODS: Fifty-six patients treated with adjuvant radiotherapy (RT) after EPP were analyzed. Four patients were treated with 3DCRT, 50 with IMRT and two with helical tomotherapy. Forty-five to 50 Gy in 25 fractions were given to the affected hemithorax and to ipsilateral mediastinum, with a simultaneous integrated boost to the sites of microscopically involved margins up to 60 Gy in 20/56 cases.
RESULTS: Three year locoregional control (LRC), distant metastasis free (DMF), disease free (DF), disease specific (DSS) and overall survival (OS) rates are 90%, 66%, 57%, 62%, and 60%, respectively.
CONCLUSION: Postoperative RT with modern techniques is an effective method to obtain excellent local control and cure rates in mesothelioma patients submitted to EPP.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22079529     DOI: 10.1016/j.radonc.2011.09.025

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  15 in total

Review 1.  Review of malignant pleural mesothelioma survival after talc pleurodesis or surgery.

Authors:  Emanuela Taioli; Maaike van Gerwen; Meredith Mihalopoulos; Gil Moskowitz; Bian Liu; Raja Flores
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

2.  Adjuvant intensity-modulated proton therapy in malignant pleural mesothelioma. A comparison with intensity-modulated radiotherapy and a spot size variation assessment.

Authors:  S Lorentini; M Amichetti; L Spiazzi; S Tonoli; S M Magrini; F Fellin; M Schwarz
Journal:  Strahlenther Onkol       Date:  2012-02-10       Impact factor: 3.621

3.  Novel radiation therapy approaches in malignant pleural mesothelioma.

Authors:  Andreas Rimner; Kenneth E Rosenzweig
Journal:  Ann Cardiothorac Surg       Date:  2012-11

4.  Extra-pleural pneumonectomy in the setting of tri-modality therapy for patients with malignant pleural mesothelioma.

Authors:  Alexander Chi; Sijin Wen; Nam P Nguyen; Geraldine Jacobson; Scot Remick; William Tse; Zhongxing Liao
Journal:  Chin J Cancer Res       Date:  2013-04       Impact factor: 5.087

5.  Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.

Authors:  Fauzia Shaikh; Marjorie G Zauderer; Donata von Reibnitz; Abraham J Wu; Ellen D Yorke; Amanda Foster; Weiji Shi; Zhigang Zhang; Prasad S Adusumilli; Kenneth E Rosenzweig; Lee M Krug; Valerie W Rusch; Andreas Rimner
Journal:  J Thorac Oncol       Date:  2017-03-21       Impact factor: 15.609

Review 6.  Management of malignant pleural mesothelioma-The European experience.

Authors:  Isabelle Opitz
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

Review 7.  Proton beam therapy for malignant pleural mesothelioma.

Authors:  Shahed N Badiyan; Jason K Molitoris; Mingyao Zhu; Erica Glass; Tejan Diwanji; Charles B Simone
Journal:  Transl Lung Cancer Res       Date:  2018-04

8.  Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma.

Authors:  Elizabeth H Baldini; William G Richards; Ritu R Gill; Brian M Goodman; Olivia K Winfrey; Hannah M Eisen; Raymond H Mak; Aileen B Chen; David E Kozono; Raphael Bueno; David J Sugarbaker
Journal:  J Thorac Cardiovasc Surg       Date:  2015-02-07       Impact factor: 5.209

9.  Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Hedy L Kindler; Nofisat Ismaila; Samuel G Armato; Raphael Bueno; Mary Hesdorffer; Thierry Jahan; Clyde Michael Jones; Markku Miettinen; Harvey Pass; Andreas Rimner; Valerie Rusch; Daniel Sterman; Anish Thomas; Raffit Hassan
Journal:  J Clin Oncol       Date:  2018-01-18       Impact factor: 44.544

10.  Systematic review of trimodality therapy for patients with malignant pleural mesothelioma.

Authors:  Christopher Cao; David Tian; Con Manganas; Phoebe Matthews; Tristan D Yan
Journal:  Ann Cardiothorac Surg       Date:  2012-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.